Next time you complain about Drug Prices and BIG PHARMA consider this

Failed study, dimmed hopes in hunt for Alzheimer's treatment


Treatment for Alzheimer's failed to slow mental decline in a widely anticipated study, ending hope that researchers at Eli Lilly had finally found a drug that does more to help those suffering from the fatal, mind-robbing disease. The pharmaceutical company's shares plunged 14 percent Wednesday before markets opened. The drug, solanezumab, missed the study's main goal when patients taking it did not experience a statistically significant slowing of cognitive decline — which involves a person's ability to remember things — compared to those taking a placebo or fake drug.

Juno Therapeutics halts midstage clinical trial after patient death


Juno Therapeutics Inc. JUNO, -28.88% shares were halted in pre-market trade Wednesday after the company said one patient in its cancer trial had died and one was "not expected to recover." The two patients both experienced brain trauma earlier in the week during a phase 2 trial for a leukemia treatment, the company said. Two patients died in early July in the same clinical trial, but the company was allowed to resume the trial without the chemotherapy drug fludarabine, which Juno believed caused the deaths in combination with the company's JCAR015 drug. This week, Juno put the trial on clinical hold

Comment: Bernie routinely hits on Pharma. Meanwhile yield in LLY is 2.66%


  1. JP, did you jump on the medical waste bandwagon? SKLN

  2. Given the size of Eli Lilly, that's a shocker that one drug would be such a big deal. My stepsister's ex-husband works in drug development there--wonder if things are not exactly comfortable in his office right now.


Any anonymous comments with links will be rejected. Please do not comment off-topic